Colorectal Cancer | Specialty

Dr. Cohen on the Preliminary Results of the GALAXY Study in CRC

July 21st 2021

Stacey A. Cohen MD, discusses the preliminary results of the ongoing GALAXY trial, part of the CIRCULATE-Japan project, in colorectal cancer.

Dr. Jones on Targeting HER2 Alterations in CRC

July 20th 2021

Jeremy C. Jones, MD, discusses targeting HER2 alterations in colorectal cancer.

GI Experts Discuss Treatment Dosing, Sequencing, and Future Directions in CRC

July 15th 2021

Jaffar A. Ajani, MD, and Zev A. Wainberg, MD, discuss FDA updates regarding the dosing schedule of cetuximab for metastatic colorectal cancer and the value of real-word data on clinical practice patterns in the community when administering this drug.

Genomics, Sidedness Guide Treatment Selection in Metastatic CRC

July 14th 2021

Zev A. Wainberg, MD, and Jaffer A. Ajani, MD, discuss how to best utilize information provided to inform treatment decisions, treatment approaches for patients with newly diagnosed RAS wild-type mCRC, and factors that affect influence selecting a 2- vs 3-drug chemotherapy regimen.

Regorafenib/Nivolumab Elicits Better Responses in pMMR/MSS CRC Without Liver Metastases

July 14th 2021

Marwan Fakih, MD, discusses the efficacy of regorafenib plus nivolumab in patients with pMMR/MSS CRC, the potential for VEGFR/PD-1 inhibitor combination regimens in this population, and future directions for research.

Dr. Jones on the Risk of Interstitial Lung Disease With Trastuzumab Deruxtecan in CRC

July 12th 2021

Jeremy C. Jones, MD, discusses the risk of interstitial lung disease with fam-trastuzumab deruxtecan-nxki in colorectal cancer.

Wainberg Weighs In on Advances in HER2+ GI Cancers

July 12th 2021

Dr. Wainberg discusses factors that help steer treatment selection in HER2-positive gastrointestinal malignancies, advances on the horizon, and more.

Dr. Hubbard on the Utility of MRD Assessment for Stage II CRC

July 1st 2021

Joleen M. Hubbard, MD, discusses the utility of minimal residual disease assessment for stage II colorectal cancer.

Adagrasib/Cetuximab Combo in KRAS G12C+ CRC Under Exploration

July 1st 2021

The combination of adagrasib and cetuximab is being investigated in patients with previously treated, advanced, KRAS G12C–mutant colorectal cancer in the international, phase 3 KRYSTAL-10 study.

Nivolumab/Ipilimumab Approved in Europe for dMMR or MSI-H Metastatic Colorectal Cancer

June 29th 2021

The European Commission has approved the combination of nivolumab plus ipilimumab for use in adult patients with mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer following previous fluoropyrimidine-based combination chemotherapy.

Sequencing Therapy in Metastatic CRC Is a Marathon, Not a Sprint

June 24th 2021

Actionable mutations identified in colorectal cancer have contributed significantly to the expansion of the therapeutic options available for patients with metastatic disease.

KRAS G12C Inhibitors in mCRC

June 22nd 2021

A brief discussion regarding current data and interest in treating appropriate patients with metastatic colorectal cancer with potent KRAS G12C selective inhibitors.

Future Directions in mCRC

June 22nd 2021

Drs Jaffer A. Ajani and Zev A. Wainberg comment on current obstacles surrounding the treatment of metastatic colorectal cancer and consider the future use of ctDNA as more is learned about the disease.

Dr. Jones on the Clinical Utility of Pembrolizumab in MSI-H CRC

June 21st 2021

Jeremy C. Jones, MD, discusses the clinical utility of pembrolizumab in microsatellite instability–high colorectal cancer.

Dr. Bekaii-Saab on the Uptake of Precision Medicine in CRC

June 17th 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the uptake of precision medicine in colorectal cancer.

Dr. Jones on the Importance of Testing for Microsatellite Instability in CRC

June 15th 2021

Jeremy C. Jones, MD, discusses the importance of testing for microsatellite instability high in colorectal cancer.

EGFR Therapy for mCRC: Dermatologic Toxicity

June 15th 2021

Best practices for managing skin rashes associated with anti-EGFR therapy for metastatic colorectal cancer.

Later-Line Treatment Options for mCRC

June 15th 2021

Recommendations for treating patients with relapsed/refractory metastatic colorectal cancer in the third-line or later settings with regorafenib or TAS-102 therapy.

Dr. Strickler on Selecting Between TAS-102 and Regorafenib in CRC

June 14th 2021

John H. Strickler, MD, discusses factors to consider when selecting between trifluridine/tipiracil and regorafenib for the treatment of patients with colorectal cancer.

Regorafenib/Nivolumab Found to be More Effective in Japanese Population vs North American in CRC

June 9th 2021